Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 0/I Study to Assess the Safety and Tolerability of XRD-0394 in Combination With Radiation Therapy in Patients With High Grade Gliomas

NCT06829173 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06829173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06829173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 0/I Study to Assess the Safety and Tolerability of XRD-0394 in Combination With Radiation Therapy in Patients With High Grade Gliomas
Lead sponsor
NYU Langone Health
Phase
Phase 1
Overall status
Recruiting
Start date
November 5, 2025
Completion date
May 31, 2031
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma